{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T21:51:18Z","timestamp":1788817878374,"version":"build-2803163510"},"reference-count":63,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2022,10,9]],"date-time":"2022-10-09T00:00:00Z","timestamp":1665273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diseases"],"abstract":"<jats:p>Anemia is a common feature of both benign and malignant hematologic diseases. Beta-thalassemia (\u03b2-thalassemia) syndromes are a group of hereditary disorders characterized by ineffective erythropoiesis, due to a genetic deficiency in the synthesis of the beta chains of hemoglobin, often accompanied by severe anemia and the need for red blood cell (RBC) transfusions. Myelodysplastic syndromes (MDS) are characterized by cytopenia(s) and ineffective hematopoiesis, despite a hypercellular bone marrow. Primary myelofibrosis (PMF) is a clonal myeloproliferative neoplasm characterized by reactive fibrosis of the bone marrow, accompanied by extramedullary hematopoiesis. Luspatercept, previously known as ACE-536, is a fusion protein that combines a modified activin receptor IIB (ActRIIB), a member of the transforming growth factor-\u03b2 (TGF-\u03b2) superfamily, with the Fc domain of human immunoglobulin G (IgG1). It has shown efficacy in the treatment of anemia due to beta \u03b2-thalassemia, MDS and PMF and recently gained approval by the Federal Drug Agency (FDA) and the European Medicines Agency (EMA) for transfusion-dependent (TD) patients with \u03b2-thalassemia and very low to intermediate-risk patients with MDS with ringed sideroblasts who have failed to respond to, or are ineligible for, an erythropoiesis-stimulating agent. In this review, we describe the key pathways involved in normal hematopoiesis and the possible mechanism of action of luspatercept, present its development and data from the most recent clinical trials in \u03b2-thalassemia, MDS and PMF, and discuss its potential use in the treatment of these hematological disorders.<\/jats:p>","DOI":"10.3390\/diseases10040085","type":"journal-article","created":{"date-parts":[[2022,10,9]],"date-time":"2022-10-09T20:49:31Z","timestamp":1665348571000},"page":"85","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Luspatercept: A New Tool for the Treatment of Anemia Related to \u03b2-Thalassemia, Myelodysplastic Syndromes and Primary Myelofibrosis"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4408-5646","authenticated-orcid":false,"given":"Eleftheria","family":"Hatzimichael","sequence":"first","affiliation":[{"name":"Department of Haematology, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45500 Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Despoina","family":"Timotheatou","sequence":"additional","affiliation":[{"name":"Medical Department, Genesis Pharma SA, Halandri, 15232 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0035-467X","authenticated-orcid":false,"given":"Epameinondas","family":"Koumpis","sequence":"additional","affiliation":[{"name":"Department of Haematology, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45500 Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonidas","family":"Benetatos","sequence":"additional","affiliation":[{"name":"Blood Bank, Preveza General Hospital, 48100 Preveza, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0142-6110","authenticated-orcid":false,"given":"Alexandros","family":"Makis","sequence":"additional","affiliation":[{"name":"Department of Child Health, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45500 Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1056\/NEJMoa1910182","article-title":"A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent beta-Thalassemia","volume":"382","author":"Cappellini","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa1908892","article-title":"Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes","volume":"382","author":"Fenaux","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.exphem.2016.08.007","article-title":"Preclinical rationale for TGF-beta inhibition as a therapeutic target for the treatment of myelofibrosis","volume":"44","author":"Ceglia","year":"2016","journal-title":"Exp. Hematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/jcph.160","article-title":"Multiple-dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA-IgG1), a novel erythropoietic agent, in healthy postmenopausal women","volume":"53","author":"Sherman","year":"2013","journal-title":"J. Clin. Pharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1182\/blood-2013-06-511238","article-title":"Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine beta-thalassemia","volume":"123","author":"Suragani","year":"2014","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/ajh.23732","article-title":"A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers","volume":"89","author":"Attie","year":"2014","journal-title":"Am. J. Hematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1182\/blood-2018-10-879247","article-title":"Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with beta-thalassemia","volume":"133","author":"Piga","year":"2019","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1038\/s41375-018-0118-9","article-title":"A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-alpha in anemic patients with low-risk MDS","volume":"32","author":"Fenaux","year":"2018","journal-title":"Leukemia"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/MOH.0000000000000231","article-title":"Novel players in beta-thalassemia dyserythropoiesis and new therapeutic strategies","volume":"23","author":"Arlet","year":"2016","journal-title":"Curr. Opin. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.3324\/haematol.2018.192518","article-title":"Normal and pathological erythropoiesis in adults: From gene regulation to targeted treatment concepts","volume":"103","author":"Valent","year":"2018","journal-title":"Haematologica"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BJ20100305","article-title":"Bone morphogenetic protein and growth differentiation factor cytokine families and their protein antagonists","volume":"429","author":"Rider","year":"2010","journal-title":"Biochem. J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"81604","DOI":"10.18632\/oncotarget.20258","article-title":"Role of growth differentiation factor 11 in development, physiology and disease","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/nm.3524","article-title":"Targeting a new regulator of erythropoiesis to alleviate anemia","volume":"20","author":"Paulson","year":"2014","journal-title":"Nat. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/ajh.24530","article-title":"2017 Clinical trials update in new treatments of beta-thalassemia","volume":"91","author":"Makis","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"358283","DOI":"10.1155\/2010\/358283","article-title":"Iron Loading and Overloading due to Ineffective Erythropoiesis","volume":"2010","author":"Tanno","year":"2010","journal-title":"Adv. Hematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1182\/blood-2018-11-876888","article-title":"Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis","volume":"133","author":"Fenaux","year":"2019","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1634\/theoncologist.2011-S3-35","article-title":"Clinical use of erythropoietic stimulating agents in myelodysplastic syndromes","volume":"16","author":"Santini","year":"2011","journal-title":"Oncologist"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1182\/blood-2008-02-139824","article-title":"Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS","volume":"112","author":"Zhou","year":"2008","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/nm.3512","article-title":"Transforming growth factor-beta superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis","volume":"20","author":"Suragani","year":"2014","journal-title":"Nat. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5224","DOI":"10.1182\/blood.V126.23.5224.5224","article-title":"GDF11 Increased in Patients with Myelodysplastic Syndrome","volume":"126","author":"Han","year":"2015","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/PPO.0000000000000169","article-title":"Treatment of Myelofibrosis: A Moving Target","volume":"22","author":"Cerquozzi","year":"2016","journal-title":"Cancer J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/ajh.25230","article-title":"Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management","volume":"93","author":"Tefferi","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1182\/blood-2002-04-1133","article-title":"Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice","volume":"100","author":"Chagraoui","year":"2002","journal-title":"Blood"},{"key":"ref_24","first-page":"5","article-title":"Bone marrow fibrosis in primary myelofibrosis: Pathogenic mechanisms and the role of TGF-beta","volume":"3","author":"Agarwal","year":"2016","journal-title":"Stem Cell Investig."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1182\/blood-2012-06-439661","article-title":"Characterization of the TGF-beta1 signaling abnormalities in the Gata1low mouse model of myelofibrosis","volume":"121","author":"Zingariello","year":"2013","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1172\/JCI82905","article-title":"Downregulation of GATA1 drives impaired hematopoiesis in primary myelofibrosis","volume":"127","author":"Gilles","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s00277-010-1019-9","article-title":"Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: Results in 40 patients","volume":"89","author":"Gaya","year":"2010","journal-title":"Ann. Hematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/HS9.0000000000000001","article-title":"Myelofibrosis-Related Anemia: Current and Emerging Therapeutic Strategies","volume":"1","author":"Naymagon","year":"2017","journal-title":"Hemasphere"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13045-021-01157-4","article-title":"Momelotinib: An emerging treatment for myelofibrosis patients with anemia","volume":"15","author":"Chifotides","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1200\/JCO.2017.73.4418","article-title":"SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naive Patients With Myelofibrosis","volume":"35","author":"Mesa","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S2352-3026(17)30237-5","article-title":"Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): A randomised, open-label, phase 3 trial","volume":"5","author":"Harrison","year":"2018","journal-title":"Lancet Haematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.2217\/fon-2020-1048","article-title":"MOMENTUM: Momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic","volume":"17","author":"Verstovsek","year":"2021","journal-title":"Future Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1111\/bjh.15964","article-title":"Deferasirox in the management of iron-overload in patients with myelofibrosis: A multicentre study from the Rete Ematologica Lombarda (IRON-M study)","volume":"186","author":"Elli","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.leukres.2018.11.012","article-title":"Deferasirox in the treatment of iron overload during myeloproliferative neoplasms in fibrotic phase: Does ferritin decrement matter?","volume":"76","author":"Campagna","year":"2019","journal-title":"Leuk. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.exphem.2006.08.016","article-title":"Adenoviral-mediated TGF-beta1 inhibition in a mouse model of myelofibrosis inhibit bone marrow fibrosis development","volume":"35","author":"Gastinne","year":"2007","journal-title":"Exp. Hematol."},{"key":"ref_38","first-page":"586","article-title":"Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss","volume":"12","author":"Raje","year":"2010","journal-title":"Curr. Opin. Mol. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1359\/jbmr.081208","article-title":"Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women","volume":"24","author":"Ruckle","year":"2009","journal-title":"J. Bone Min. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1182\/blood.2019001057","article-title":"Lack of Gdf11 does not improve anemia or prevent the activity of RAP-536 in a mouse model of beta-thalassemia","volume":"134","author":"Guerra","year":"2019","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood.V128.22.2463.2463","article-title":"Pharmacokinetics and Exposure-Response of Luspatercept in Patients with Beta-Thalassemia: Preliminary Results from Phase 2 Studies","volume":"128","author":"Chen","year":"2016","journal-title":"Blood"},{"key":"ref_42","unstructured":"Taher, A.T., Cappellini, M.D., Kattamis, A., Voskaridou, E., Perrotta, S., Piga, A., Filosa, A., Porter, J.B., Coates, T.D., and Forni, G. (2021, January 9\u201317). The BEYOND study: Results of a phase 2, double-blind, randomized, placebo-controlled multicenter study of luspatercept in adult patients with non-transfusion dependent beta-thalassemia. Proceedings of the 26th Congress of the European Hematology Association, Hague, The Netherlands."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1182\/blood-2021-148535","article-title":"Luspatercept Improves Quality of Life and Reduces Red Blood Cell Transfusion Burden in Patients with Non-Transfusion-Dependent \u03b2-Thalassemia in the BEYOND Trial","volume":"138","author":"Kattamis","year":"2021","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e29334","DOI":"10.1097\/MD.0000000000029334","article-title":"Recurrent spinal cord compression due to extramedullary hematopoiesis in thalassemia patient: Case report","volume":"101","author":"Abbarh","year":"2022","journal-title":"Medicine"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Alashkar, F., Klump, H., Lange, C.P., Proske, P., Schussler, M., Yamamoto, R., Carpinteiro, A., Berliner, C.A., Schlosser, T.W., and Roth, A. (2022). Luspatercept, a two-edged sword in beta-thalassemia-associated paravertebral extramedullary hematopoietic masses (EHMs). Eur. J. Haematol., 1\u20138.","DOI":"10.1111\/ejh.13849"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/S1470-2045(17)30615-0","article-title":"Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): A multicentre, open-label phase 2 dose-finding study with long-term extension study","volume":"18","author":"Platzbecker","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2018-99-110805","article-title":"The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions","volume":"132","author":"Fenaux","year":"2018","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Zeidan, A.M., Platzbecker, U., Garcia-Manero, G., Sekeres, M.A., Fenaux, P., DeZern, A.E., Greenberg, P.L., Savona, M.R., Jurcic, J.G., and Verma, A. (2022). Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts. Blood.","DOI":"10.1182\/blood.2022016171"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood.2021012589","article-title":"Neutrophil and platelet increases with luspatercept in lower-risk MDS: Secondary endpoints from the MEDALIST trial","volume":"139","author":"Mufti","year":"2022","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Oliva, E.N., Platzbecker, U., Garcia-Manero, G., Mufti, G.J., Santini, V., Sekeres, M.A., Komrokji, R.S., Shetty, J.K., Tang, D., and Guo, S. (2022). Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 Trial. J. Clin. Med., 11.","DOI":"10.3390\/jcm11010027"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1182\/blood-2021-145723","article-title":"Analysis of Duration of Response, Exposure-Adjusted Safety and Progression to Acute Myeloid Leukemia (AML) for Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Receiving Luspatercept in the MEDALIST Study","volume":"138","author":"Platzbecker","year":"2021","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1182\/blood-2020-136705","article-title":"Effect of Luspatercept on Biomarkers of Erythropoiesis in Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the Medalist Trial","volume":"136","author":"Platzbecker","year":"2020","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2020-137232","article-title":"Efficacy and Safety of Luspatercept Treatment in Patients with Myelodysplastic Syndrome\/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS\/MPN-RS-T): A Retrospective Analysis from the Medalist Study","volume":"136","author":"Komrokji","year":"2020","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"E210","DOI":"10.1002\/ajh.26533","article-title":"Real-world experience with luspatercept and predictors of response in myelodysplastic syndromes with ring sideroblasts","volume":"97","author":"Farrukh","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1182\/blood-2019-122546","article-title":"A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia","volume":"134","author":"Gerds","year":"2019","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.blre.2008.04.001","article-title":"Thalassemia and hypercoagulability","volume":"22","author":"Taher","year":"2008","journal-title":"Blood Rev."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1182\/blood-2015-01-622522","article-title":"RAP-011 improves erythropoiesis in zebrafish model of Diamond-Blackfan anemia through antagonizing lefty1","volume":"126","author":"Ear","year":"2015","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Parisi, S., Finelli, C., Fazio, A., De Stefano, A., Mongiorgi, S., Ratti, S., Cappellini, A., Billi, A.M., Cocco, L., and Follo, M.Y. (2021). Clinical and Molecular Insights in Erythropoiesis Regulation of Signal Transduction Pathways in Myelodysplastic Syndromes and beta-Thalassemia. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22020827"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/s41375-019-0448-2","article-title":"Transforming growth factor (TGF)-beta pathway as a therapeutic target in lower risk myelodysplastic syndromes","volume":"33","author":"Bewersdorf","year":"2019","journal-title":"Leukemia"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"106430","DOI":"10.1016\/j.leukres.2020.106430","article-title":"Myelo-deception: Luspatercept & TGF-Beta ligand traps in myeloid diseases & anemia","volume":"97","author":"Feld","year":"2020","journal-title":"Leuk. Res."},{"key":"ref_62","unstructured":"Cappellini, M.D., Cohen, A., Porter, J., Taher, A., and Viprakasit, V. (2014). Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT), Thalaessemia international Federation. [3rd ed.]."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/ejhf.708","article-title":"Heart failure in haemoglobinopathies: Pathophysiology, clinical phenotypes, and management","volume":"19","author":"Farmakis","year":"2017","journal-title":"Eur. J. Heart Fail."}],"container-title":["Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-9721\/10\/4\/85\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:48:32Z","timestamp":1760143712000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-9721\/10\/4\/85"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,9]]},"references-count":63,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["diseases10040085"],"URL":"https:\/\/doi.org\/10.3390\/diseases10040085","relation":{},"ISSN":["2079-9721"],"issn-type":[{"value":"2079-9721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,9]]}}}